An Early Phase 1 interventional study of Adenosine and Regadenoson in MRI Scans, sponsored by University of Utah. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-07.
Sponsored by University of Utah · Early Phase 1, Interventional, and Health services research
This study's main specific aims are;
Heart failure with preserved ejection fraction (HFpEF) is currently being studied intensely as several large trials of drug therapies have failed to benefit patients. Better characterization of these patients is important, and there are open questions regarding microvascular disease and remodeling in the HFpEF population. New MRI methods could be ideal to better characterize and understand HFpEF and its response to treatments. This project seeks to develop, evaluate and apply new MRI methods for high-end perfusion imaging. These methods will estimate endo/epi ratios across the cardiac cycle in free-breathing studies, which will provide new information about microvascular disease. This is of particular value for assessing HFpEF.
The idea of this project is to combine new techniques for quantitative cardiac perfusion MRI imaging that would be ideally suited for answering open questions regarding HFpEF and for studying microvascular disease. The methods could potentially also predict patients who might respond to particular drug therapies.
The new techniques include "simultaneous multi-slice" imaging which has not been used this way for myocardial perfusion imaging. In particular, we are developing an innovative hybrid of the standard saturation pulse and steady state spoiled gradient echo acquisitions. We also are developing a new method for using 3D "stack of stars" + 2D slice in the same scan for arterial input function assessment to quantify perfusion, and new methods for measuring T1.
University of Utah is the lead sponsor of 969 studies on the registry; 178 are open to participants now.
Of its 107 completed or terminated interventional studies of FDA-regulated products, 62 (58%) have results posted.
Counted across the registry records on this site, refreshed daily.
All participants will be over the age of 18 and able to provide consent
Exclusion Criteria:
Adenosine Regadenoson O-15 Labeled radioactive water MRI PET Imaging
Drug: Adenosine · Drug: Regadenoson · Drug: O-15 labeled radioactive water · Device: MRI · Device: PET Imaging
Adenosine: 0.14mg/kg/min for 6 min. IV injection for MRI perfusion
Also known as: Adenoscan, Adenocard
0.4mg in 5ml, given as a rapid (10 seconds) IV injection for MRI perfusion.
Also known as: Lexiscan
O-15 labeled radioactive water: Up to 50mCi IV injection at rest and again at hyperemia for PET Imaging
Also known as: O-15 water
Pass dynamic contrast enhanced MRI scans will be performed at rest and during hyperemia caused by either adenosine infusion or regadenoson
Quantitative PET imaging with O-15 labeled radioactive water will be given at a different day
Also known as: Positron Emission Tomography Imaging
Myocardial perfusion measured with MRI
Myocardial perfusion measured with Magnetic Resonance Imaging (MRI) at rest and vasodilation
Time frame: Time in the scanner to be 60-90 minutes.
ECV measures
Extracellular volume (ECV) measures from T1 mapping pre- and post-contrast
Time frame: One year
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Utah